Clickbait. For $400 you can unlock this exclusive report: Big Pharma has lobbyists! Wait... what?
The real issue with Sarepta is complacency. By god, I think they considered themselves Big Pharma. Dumb asses should have raised money at $100+ before licensing with Arrowhead. (Avoro has a big position in Arrowhead as well as Sarepta, as per last filing.) Now they are forced to cut 36% of their workforce and have to contend with a $1B note due in 2027. Well, it was basically free money at 1.25% and can surely be refinanced, worst case scenario? To be honest, I am horrible with financials.
Sarepta had $850 in cash last quarter, $1B in annual revenue exclusive of the "controversial" Elevidys, and 85% margins on all of these drugs. Arrowhead seems to represent next generation technology, so ok. Sarepta's viral vector may be seen as barbaric ten years from now-- today, patients do not have any alternative. The main risk here is a death in ambulatory DMD after 700+ doses, but patient families will probably still want the therapy anyway.
Believe it or not, Trump (after canning Prasad) is actually the voice of reason in all of this contentious, self-serving muck:
July 31, 2025
The Trump administration is considering a major overhaul of FDA’s biologics division that would split the Center for Biologics Evaluation and Research (CBER) into two separate bodies -- one focused solely on vaccines and another on therapeutic biologics, according to a person familiar with the discussion.
The Arrowhead transaction:
 |
